Open access under the Elsevier OA license.
Summary
The potential of MRI to estimate radiation-absorbed dose distributions of holmium-166 loaded poly (L-lactic) microsphere ( 166 Ho-PLLA-MS) was investigated using the dose point-kernel convolution method. Quantitative MRI was demonstrated to provide accurate three-dimensional 166 Ho-PLLA-MS biodistributions and by direct proportion 166 Ho activity distributions, which facilitated localized intrahepatic radiation-absorbed dose estimation by convolution with a 166 Ho dose point-kernel. Good qualitative and quantitative agreement was observed with SPECT-based radiation-absorbed dose Purpose: To investigate the potential of magnetic resonance imaging (MRI) for accurate assessment of the three-dimensional 166 Ho activity distribution to estimate radiation-absorbed dose distributions in 166 Ho-loaded poly (L-lactic acid) microsphere ( 166 Ho-PLLA-MS) liver radioembolization. Methods and Materials: MRI, computed tomography (CT), and single photon emission CT (SPECT) experiments were conducted on an anthropomorphic gel phantom with tumorsimulating gel samples and on an excised human tumor-bearing liver, both containing known amounts of 166 Ho-PLLA-MS. Three-dimensional radiation-absorbed dose distributions were estimated at the voxel level by convolving the 166 Ho activity distribution, derived from quantitative MRI data, with a 166 Ho dose point-kernel generated by MCNP (Monte Carlo N-Particle transport code) and from Medical Internal Radiation Dose Pamphlet 17. MRI-based radiationabsorbed dose distributions were qualitatively compared with CT and autoradiography images and quantitatively compared with SPECT-based dose distributions. Both MRI-and SPECTbased activity estimations were validated against dose calibrator measurements. Results: Evaluation on an anthropomorphic phantom showed that MRI enables accurate assessment of local 166 Ho-PLLA-MS mass and activity distributions, as supported by a regression coefficient of 1.05 and a correlation coefficient of 0.99, relating local MRIbased mass and activity calculations to reference values obtained with a dose calibrator. Estimated MRI-based radiation-absorbed dose distributions of 166 Ho-PLLA-MS in an ex vivo human liver visually showed high correspondence to SPECT-based radiationabsorbed dose distributions. Quantitative analysis revealed that the differences in local and total amounts of 166 Ho-PLLA-MS estimated by MRI, SPECT, and the dose calibrator were within 10%. Excellent agreement was observed between MRI-and SPECT-based doseevolume histograms. Conclusions: Quantitative MRI was demonstrated to provide accurate three-dimensional 166 Ho-PLLA-MS activity distributions, enabling localized intrahepatic radiation-absorbed
Introduction
During the past decade, over 30,000 patients suffering from unresectable primary or metastatic liver tumors were treated by hepatic arterial radioembolization (RE) with high-energy b-radiationeemitting microspheres (1, 2) . Apart from the amount of radioactivity that is administered, the efficacy of this type of internal radiation therapy is postulated to depend on the intrahepatic dose distribution (2e4). By administering the microspheres intra-arterially, the predominance of the arterial supply to liver tumors is exploited, generally resulting in a high tumor-to-normal tissue ratio (5) . However, the large variation in vascularity of tumor and liver observed between patients necessitates extensive treatment planning to ensure a favorable dose distribution in each individual patient (6) . The currently used radioactive microspheres for RE contain the b-emitting radionuclide 90 Y, which does not facilitate quantitative biodistribution assessment, despite developments involving Bremsstrahlung imaging (7) and more recently positron emission tomography (8) . Therefore, in clinical practice, 99m Tc macroaggregated albumin (MAA) is used as a surrogate, aiming to estimate the lung-shunt fraction, to detect extrahepatic deposition, and to assess intrahepatic dose distributions using planar scintigraphy and single photon emission computed tomography (SPECT). The differences in size distribution (10e90 mm), number of particles, shape, density, and consequently hemodynamic properties of 99m Tc-MAA particles, along with the sizeable amount (up to 10%) that is well below 30 mm, are hypothesized to cause the discrepancies observed between the biodistribution of 99m Tc-MAA particles and the 90 Y microspheres (7) . 166 Ho-loaded poly (L-lactic acid) microspheres ( 166 Ho-PLLA-MS) constitute an alternative RE device, which currently is the subject of a Phase I clinical trial (9) . 166 (6, 10e12) . Interestingly, holmium is highly paramagnetic, which is independent of radioactivity, making both neutron-activated and nonactivated Ho-PLLA-MS an ideal MR contrast agent (12, 13) . These properties yield a single microparticle suitable for RE with the potential of in vivo quantitative biodistribution assessment. Additionally, MRIguided catheterization and administration of Ho-PLLA-MS was shown to allow real-time in vivo monitoring of microsphere delivery to the tumor site (13, 14) . More recently, we reported the development of a fast quantitative MR imaging technique that enables accurate quantification of the distribution of Ho-PLLA-MS at the level of a voxel (15) .
The purpose of this study was to test the hypothesis that MRI can be used to accurately assess the 3D 166 Ho-PLLA-MS activity distribution to enable radiation-absorbed dose estimation for treatment planning optimization and follow-up of transcatheter liver RE. To this end, MRI experiments were conducted on an anthropomorphic gel phantom and on an ex vivo human liver with tumors after postexcision arterial RE with 166 Ho-PLLA-MS. By the use of a 3D 166 Ho dose-point kernel, and after transformation of the quantitative MRI-based 166 Ho-PLLA-MS biodistributions into 3D 166 Ho activity distributions, radiation-absorbed dose distributions were estimated by convolution. The results were validated qualitatively and quantitatively by CT, SPECT, autoradiography, and dose calibrator measurements.
Methods and Materials

Phantom preparation
An ellipse-shaped Perspex phantom (short axis Z 19 cm; long axis Z 30 cm; height Z 7 cm; volume w3 L) was filled with agarose gel and 10 cone-hemisphere-shaped (w2 Â 2.5 Â 2.5 cm, w7 mL) tumor-simulating gel samples. Agarose gel (2%) was doped with 28 mg/mL MnCl 2 $4H 2 O to mimic the T 1 relaxation properties of liver tissue (gel density Z 0.99 g/cm 3 ). Small amounts of radioactive 166 Ho-PLLA-MS were administered to the liquid gel in a mold. Ho-PLLA-MS (17% by mass holmium, diameter [mean AE SD] Z 30 AE 5 mm) were prepared under good manufacturing practice as previously described (16) . The specific activity (S A ) of 166 Ho-PLLA-MS, after activation by thermal neutron bombardment for 2 hours (6, 17) , was determined to be 5.83 MBq/mg using a dose calibrator (VDC-404, Veenstra Instrumenten B.V., Joure, The Netherlands), which was calibrated by the Dutch measurement institute (NMI, Delft, The Netherlands) according to NEN-EN-ISO/IEC 17055:2005 criteria. Using the same dose calibrator, the activity in each single "tumor" was determined. A total activity of 152 MBq in 26 mg of 166 Ho-PLLA-MS was distributed over eight "tumors" with the following amounts: 1.16, 1.16, 2.28, 2.86, 3.52, 3.95, 5.04, and 6.16 mg. As a control, two "tumors" without microspheres were made. The used amounts provided a realistic concentration range, in the knowledge that in clinical practice amounts of 60 mg (scout dose) to 600 mg (treatment dose) are infused into an average liver volume of 1.5 l (9), and in the expectation that tumor-to-normal tissue ratios vary between 2 and 8 (5, 10) .
Ex vivo liver preparation
To investigate the feasibility of MRI-based radiation-absorbed dose estimation in a more realistic situation, an ex vivo tumorbearing human liver (2.4 kg) was prepared. A total amount of 606.5 mg 166 Ho-PLLA-MS (17% by mass) with an activity of 418 MBq (S A Z 0.689 MBq/mg) was prepared to be infused in the hepatic artery of the liver after excision. Before infusion, the liver was submersed in purified water doped with 28 mg/mL MnCl 2 H 2 O to mimic the T 1 relaxation properties of liver tissue. The total administered amount of radioactivity was determined retrospectively by subtracting the activity left in the vial, syringe, tubes, and cloths, as determined using the dose calibrator.
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MR imaging
The MR imaging experiments were performed on a clinical 3T MR scanner (Achieva, Philips Healthcare, The Netherlands 
SPECT imaging
Before SPECT, the liver was embedded in a carboxylmethyl cellulose solution (2.5%) containing four 166 HoCl 3 markers as references, and was kept at À20 C for 24 hours. SPECT was acquired using a dual-headed gamma camera equipped with medium-energy general purpose collimators (Vertex MCD, Philips Healthcare). Scanning line sources containing 5.5 GBq 153 Gd were used for attenuation correction (energy window: 100 keV AE 10%). The 166 (11) . To obtain optimal image resolution, 40 iterations were used. No postreconstruction filter was applied.
Autoradiography
The frozen carboxylmethyl cellulose-embedded liver was cut into 6-mm-thick slices. The slices were placed on a storage phosphor screen (8 min exposure time/slice) and scanned using a Storm imaging system (GE Healthcare Life Sciences, Diegem, Belgium;
200 mm pixel size).
Data analysis MR images
The effective transverse relaxation rate (R 2 * ) was determined voxelwise using a least-squares fitting algorithm, assuming monoexponential signal decay (15) . Fig. 1 . For Ho-PLLA-MS (17% by mass) at 3T, the relaxivity r 2 * was determined to be 180 s À1 mg À1 mL (15) . The concentration maps of the ex vivo liver were upsampled to a slice thickness of 3 mm using a linear interpolation scheme, leaving the total amount of Ho-PLLA-MS unaffected. This resulted in 3-mm cubic voxel sizes for all data. Multiplication of the concentration maps by the Fig. 1 . Flowchart indicating the sequence of steps taken to derive three-dimensional voxel-based 166 Ho radiation-absorbed dose distributions from magnetic resonance imaging (MRI) data. Ho-PLLA-MS Z 166 Ho-loaded poly (L-lactic acid) microsphere.
voxel volume provided the total amount of Ho-PLLA-MS present in each voxel (in milligrams). Then, multiplication by the specific activity (in MBq/mg) of the administered microspheres at the moment of infusion provided maps of the activity per voxel (in MBq/voxel).
SPECT images
The SPECT reconstructions provided an absolute quantitative 3D activity distribution in Mbq/voxel after multiplication with a previously determined calibration factor specific for 166 Ho (11) . The SPECT reconstructions were upsampled using a linear interpolation scheme to an isotropic voxel size of 3 mm. To obtain the amount of Ho-PLLA-MS in milligrams per voxel, the 3D activity distribution was divided by the specific activity.
Radiation-absorbed dose calculations
A 166 Ho dose point-kernel (PK) was calculated using the Monte Carlo N-Particle transport code (MCNP5; vs. 1.20; LANL, Los Alamos, NM) according to the method described in Medical Internal Radiation Dose (MIRD) Pamphlet 17 (18), assuming a tissue density for liver tissue of 1.06 g/cm 3 , according to International Commission on Radiation Units and Measurements Report 44 (19) . Default particle physics settings for MCNP were used (energy cutoff 1 keV, photoelectric effect, and coherent photon scattering turned on, Brehmsstrahlung and x-ray production by electrons). The particle transport of the lowenergy conversion and Auger electrons was not calculated because the range of these particles in liver tissue is well below the 3-mm voxel size; the total electron energy (27 keV/decay) was considered to be locally deposited in each source voxel. The 3D point-symmetric dose PK was generated on a 29 Â 29 Â 29 matrix, with the source located in the center, providing the absorbed energy in 3-mm cubic voxels per decay for the emission spectrum of 166 Ho as a function of the source-to-target voxel center-to-center distance (Fig. 2) . Radiation-absorbed dose distributions were estimated by convolving the MRI-and SPECT-based activity distributions with the 166 Ho dose kernel, after converting absorbed energies to dose per activity by taking into account the 166 Ho decay constant and voxel mass and assuming complete trapping of activity.
Volume of interest analysis
The total amount of Ho-PLLA-MS in the gel phantom was determined for each "tumor" separately by a volume of interest (VOI) analysis on R 2 * maps and SPECT reconstructions. Cylinder-shaped VOIs were manually drawn around each "tumor," taking into account a 5-mm margin to ensure that the entire "tumor" was included. Summation of the included amount of Ho-PLLA-MS in milligrams per voxel provided the total amount of Ho-PLLA-MS in milligrams for each "tumor" for both imaging modalities, which also reflects the total activity per "tumor" when dividing by S A . The excised liver was manually segmented on T 2 * -weighted MR images to enable a VOI analysis of the whole liver. For analysis of the SPECT data, a VOI was defined by segmenting the liver on three orthogonal projections of the 3D activity maps. The estimated total amount and activity of 166 Ho-PLLA-MS were compared with the values obtained with the dose calibrator. Maximum-intensity projections and summed-intensity projections (SIPs) were calculated for qualitative comparison. For quantitative analysis using a cumulative doseevolume histogram, the administered activity was extrapolated to that for a uniform average liver dose of 40 Gy. For a 2.4-kg liver, 6.0 GBq of 166 Ho activity is required to deliver 40 Gy (9) , which is simulated by multiplying the net activity administered to the liver (368 MBq) by a factor of 16.3 (368 MBq Â 16.3 Z 6.0 GBq). Finally, a single slice analysis was performed by comparing estimated MRI-based absorbed dose maps with CT and SPECT-based absorbed dose maps with autoradiography.
Results
In vitro experiments
The absorbed energy in liver tissue per decay for the emission spectrum of 166 Ho as a function of the distance between source and the center of a 3-mm cubic target voxel were generated by MCNP and from MIRD Pamphlet 17 (Fig. 2) and were subsequently used to construct a 166 Ho dose PK. Good agreement was observed both visually and quantitatively between MRI-based and SPECT-based radiation-absorbed dose maps (Fig. 3) . The MRI-based dose distributions clearly reflected the actual conehemisphere shape of the tumor-simulating gel samples containing 166 Ho-PLLA-MS; however, the SPECT-based dose maps depicted smoothed and sphere-shaped dose distributions. These differences are related to the inherently low resolution of SPECT and the subsequent upsampling (4.72 mm to 3 mm) necessary to match the cubic voxel size of the dose PK, leading to increased partial volume effects and spatial blurring at the edges of the "tumor." In the center of the "tumors," where partial volume effects have less influence, both modalities presented similar absorbed dose values, with maximal values of 65 Gy. In some areas outside the "tumors," where no activity was present based on prior knowledge, nonzero values were found. These offsets in absorbed dose directly related to macroscopic magnetic field inhomogeneities induced by sharp edges in the Perspex phantom, which locally increased the R 2 * value and thereby falsely indicated the presence of 166 Ho-PLLA-MS, as was also Fig. 2 . The absorbed energy in 3-mm cubic voxels in liver tissue per decay for the emission spectrum of 166 Ho as a function of the distance between source and target voxel centers.
reflected by the positive intercept of the linear regression curve presented in Fig. 4a .
The VOI analysis of the tumor-simulating gel samples revealed good agreement between the total amounts per "tumor" of Ho-PLLA-MS as determined by MRI and by both SPECT and the dose calibrator (Fig. 4 ). This was demonstrated by linear regression analysis, relating SPECT-and MRI-based total amount and activity of 166 Ho-PLLA-MS per "tumor" to the values obtained with the dose calibrator, revealing a slope of 1.00 with R 2 Z 0.99 for SPECT data, and a slope of 1.05 with R 2 Z 0.99 for MRI data.
Ex vivo liver
Analysis of the MRI data provided a total amount of 521 mg of Ho-PLLA-MS in the ex vivo liver, containing a total activity of 359 MBq. This agrees well (À2.4%) with the values found by the dose calibrator (534 mg containing 368 MBq). SPECT overestimated the dose calibrator measurements by 7.9% (576 mg containing 397 MBq). Cumulative doseevolume histograms obtained from MRI-and SPECT-based absorbed dose estimations in the liver showed a high degree of resemblance (Fig. 5f) . This was visually supported by the maximum-intensity projections 166 Ho-loaded poly (L-lactic acid) microsphere in the "tumors" as determined with magnetic responance imaging (MRI) (a) and with single photon emission computed tomography (SPECT) (b), plotted against the known amounts of 166 Ho-loaded poly (L-lactic acid) microsphere as determined with a dose calibrator. The correlation between MRI and SPECT is also demonstrated (c).
( Fig. 5a and d) and SIPs ( Fig. 5b and e ) of the SPECT-and MRIbased dose maps, respectively, which depict similar dose distributions macroscopically. The CT SIP image (Fig. 5c ) shows excellent visual agreement with the biodistribution of Ho-PLLA-MS as depicted in the MRI SIP, both having been obtained from the same experimental setup, which prevented translation, rotation, and deformation. Figure 6aec shows a T 2 * -weighted MR image of the liver, the accompanying MRI-based absorbed dose distribution, and a CT image of the same slice, in which Ho-PLLA-MS is depicted hyperintense (12) . Excellent visual agreement can be observed between the hypointensities in the T 2 * -weighted image, the high values in the absorbed dose map, and the hyperintensities in the CT image. Although macroscopically and quantitatively MRI-and SPECT-based dose maps ( Fig. 6b and e) show similar absorbed dose distributions, clear differences can be observed as well. Apart from differences related to acquisition voxel size, differences related to translation and rotation can be attributed to the fact that before SPECT, the liver was transferred into a setup with radioactive markers used as landmarks to enable comparison of SPECT and autoradiographic imaging. These autoradiographs showed a high degree of visual resemblance with the SPECT-based absorbed dose distributions (Fig. 6f ). However, as may be expected, the SPECT reconstruction and dose map depict lower resolution and smoothed distributions compared with the autoradiograph.
Discussion
This study demonstrates that quantitative MRI enables accurate estimation of the 166 Ho-PLLA-MS activity distribution in vitro and in ex vivo human tumor-bearing liver in a scan duration equal to a single breath-hold. Furthermore, it was shown that by convolution of a 3D MRI-based activity distribution with a 166 Ho dose PK, it is possible to estimate the radiation-absorbed dose distribution. These results, in combination with the fact that MRI provides high resolution and excellent soft tissue contrast, has relatively short acquisition times, and allows real-time monitoring during microsphere delivery to the tumor site (13, 14) , suggest that MRI is an attractive modality to perform treatment planning and follow-up of transcatheter RE of hepatic malignancies with 166 Ho-PLLA-MS in a clinical setting. Interestingly, the sensitivity of MRI for Ho-PLLA-MS is independent of radioactivity, enabling intraprocedural biodistribution assessment and dose prediction using "cold" Ho-PLLA-MS and the acquisition of follow-up scans after treatment long after 166 Ho has decayed.
The accuracy of MRI-based absorbed dose estimations of 166 Ho-PLLA-MS is directly related to the accuracy of the Ho-PLLA-MS biodistribution assessment. In this regard, two limitations should be addressed. First, the MRI-based approach provides a single concentration value for each volume element, assuming an average activity in the entire voxel. This will not be the case in clinical practice, given that RE is an intravascular procedure that provides a highly inhomogeneous particle distribution at the level of the microvasculature. When a dose PK is applied for absorbed dose estimation in such a case, a homogeneous tissue composition and uniform radionuclide distribution within voxels is implicitly but falsely assumed, which may be expected to affect the accuracy of the dose PK convolution method. These well-known characteristics of voxel dosimetry have already been addressed by Bolch et al. (18) . Second, the accuracy of the MRI-based biodistribution assessment is limited by local variations of baseline R 2 * values in the liver, inasmuch as these variations complicate accurate determination of the increase of the R 2 * value (DR 2 * ) attributed to the presence of Ho-PLLA-MS. It is important to be aware of this limitation; however, it should also be realized that its maximum influence can easily be predicted and therefore taken into account in the treatment optimization (e.g., an erroneous increase of R 2 * by 10 s À1 translates to a local concentration increase of 0.05 mg/ mL (Z DR 2 * /r 2 * )).
When higher accuracy and consistency are needed, for example for pretreatment intrahepatic dose prediction, both the baseline R 2 * map and the postadministration R 2 * map could be acquired in the same scan session. This would ensure intrinsic image registration and enable voxelwise subtraction of spatially varying baseline R 2 * values, leading to potentially very accurate DR 2 * maps and activity maps because tissue variability can be overcome. In practice, this will require MRI-guided catheterization and administration of 166 Ho-PLLA-MS. Our group has previously demonstrated the feasibility of this method in pigs (14) ; however, the current absence of MR-compatible and visible guidewires and catheters approved for clinical use is an important limiting factor. Recent developments in this field are promising and may be expected to enable fully MRI-guided catheter-directed RE (20) . Such an MRI-guided approach will be particularly useful for patient-specific localized treatment, as is provided in radiation segmentectomy (3) (in which RE is selectively performed in only one or two predefined hepatic segments), which may be expected to increase the safety and efficacy of RE (3).
In conclusion, quantitative MRI was demonstrated in this study to provide accurate 3D 166 Ho-PLLA-MS activity distributions at the voxel level, facilitating localized intrahepatic radiationabsorbed dose estimation by convolution with a 166 Ho dose PK to enable RE treatment planning optimization and evaluation. 
